OncoZenge Valuation
Is 8LY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8LY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 8LY's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 8LY's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8LY?
Key metric: As 8LY barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 8LY's PB Ratio? | |
|---|---|
| PB Ratio | 3.3x |
| Book | SEK 12.45m |
| Market Cap | SEK 40.94m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11702.6x |
| Enterprise Value/EBITDA | 4.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 8LY's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.9x | ||
93M1 MPH Health Care | 0.3x | -65.7% | €105.3m |
B8FK Biofrontera | 0.9x | n/a | €16.4m |
SBX SynBiotic | 1.8x | 107.0% | €27.9m |
0RX Redx Pharma | 16.6x | -22.3% | €65.0m |
8LY OncoZenge | 3.3x | 93.3% | €40.9m |
Price-To-Book vs Peers: 8LY is good value based on its Price-To-Book Ratio (3.3x) compared to the peer average (5.1x).
Price to Book Ratio vs Industry
How does 8LY's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 12 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: 8LY is expensive based on its Price-To-Book Ratio (3.3x) compared to the European Pharmaceuticals industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is 8LY's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 3.3x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 8LY's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.74
7D
1.9%
1Y
-7.4%
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Merck
US$252.6b
Operates as a healthcare company worldwide.
6MK
US$97.10
7D
6.7%
1Y
3.9%